Nasal vaccine to prevent COVID-19 passes first tests
Better than conventional vaccines: Protection at the site of infection
Coronaviruses spread primarily through the air. When infected people speak, cough, sneeze or laugh, they expel droplets of saliva containing the virus. Other people then breathe in these airborne pathogens and become infected themselves. A research team in Berlin decided to try to fight the virus that causes COVID-19 where it first takes hold: the mucous membranes of the nose, mouth, throat, and lungs. To do so, the scientists developed a live attenuated SARS-CoV-2 vaccine that is administered through the nose. In the latest issue of the journal “Nature Microbiology”, the interdisciplinary team describes how this live attenuated vaccine confers better immunity in hamsters than vaccines injected into muscle.
Already in the fall of last year, two nasal vaccination formulations were approved for use in India and China. These contain modified adenoviruses – which typically cause respiratory or gastrointestinal illnesses – that are self-attenuating, meaning they either replicate poorly or stop replicating altogether, and therefore never trigger disease. Other live nasal vaccines are currently undergoing development and testing around the world.
Protection at the site of infection
The benefits of a nasal vaccine go far beyond just providing an alternative for people afraid of needles. When a vaccine is injected, it infers immunity primarily in the blood and throughout the entire body. However, this means that the immune system only detects and combats coronaviruses relatively late on in an infection, as they enter the body via the mucous membranes of the upper respiratory tract. “It is here, therefore, that we need local immunity if we want to intercept a respiratory virus early on,” explains the study’s co-last author Dr. Jakob Trimpert, a veterinarian and research group leader at the Institute of Virology at Freie Universität Berlin.
“Nasal vaccines are far more effective in this regard than injected vaccines, which fail or struggle to reach the mucous membranes,” emphasizes Dr. Emanuel Wyler, another co-last author. He has been researching COVID-19 since the start of the pandemic as part of the RNA Biology and Posttranscriptional Regulation Lab, which is led by Professor Markus Landthaler at the Berlin Institute for Medical Systems Biology of the Max Delbrück Center (MDC-BIMSB).
In an ideal scenario, a live intranasal vaccine stimulates the formation of the antibody immunoglobulin A (IgA) directly on site, thus preventing infection from occurring in the first place. IgA is the most common immunoglobin in the mucous membranes of the airways. It is able to neutralize pathogens by binding to them and preventing them from infecting respiratory tract cells. At the same time, the vaccine stimulates systemic immune responses that help provide effective overall protection from infection.
“Memory T cells that reside in lung tissue play a similarly useful role to antibodies in the mucosa,” explains Dr. Geraldine Nouailles, an immunologist and research group leader at the Department of Pneumology, Respiratory Medicine, and Intensive Care Medicine at Charité. “These white blood cells remain in affected tissue long after an infection has passed and remember pathogens they have encountered before. Thanks to their location in the lungs, they can respond quickly to viruses that enter through the airways.” The co-first author draws attention to one of the observations the team made during their study: “We were able to show that prior intranasal vaccination results in the increased reactivation of these local memory cells in the event of a subsequent SARS-CoV-2 infection. Needless to say, we were particularly pleased with this result.”
Local immunity impedes viral infection
The scientists tested the efficacy of the newly developed intranasal COVID-19 vaccine on hamster models that had been established by Trimpert and his team at Freie Universität Berlin at the beginning of the pandemic. These rodents are currently the most important non-transgenic model organisms for research into the novel coronavirus, as they can be infected with the same virus variants as humans and develop similar symptoms. They found that after two doses of the vaccine, the virus could no longer replicate in the model organism. “We witnessed strong activation of the immunological memory, and the mucous membranes were very well protected by the high concentration of antibodies,” Trimpert explains. The vaccine could therefore also significantly reduce the transmissibility of the virus.
In addition, the scientists compared the efficacy of the live attenuated vaccine with that of vaccines injected into the muscle. To do so, they vaccinated the hamsters either twice with the live vaccine, once with the mRNA and once with the live vaccine, or twice with an mRNA or adenovirus-based vaccine. Then, after the hamsters were infected with SARS-CoV-2, they used tissue samples from the nasal mucosa and lungs to see how strongly the virus was still able to attack the mucosal cells. They also determined the extent of the inflammatory response using single-cell sequencing.
“The live attenuated vaccine performed better than the other vaccines in all parameters,” Wyler summarizes. This is probably due to the fact that the nasally administered vaccine builds up immunity directly at the viral entry site. In addition, the live vaccine contains all components of the virus – not just the spike protein, as is the case with the mRNA vaccines. While spike is indeed the virus’s most important antigen, the immune system can also recognize the virus from about 20 other proteins.
Better than conventional vaccines
The best protection against the SARS-CoV-2 was provided by double nasal vaccination, followed by the combination of a muscular injection of the mRNA vaccine and the subsequent nasal administration of the live attenuated vaccine. “This means the live vaccine could be particularly interesting as a booster,” says the study’s co-first author Julia Adler, a veterinarian and doctoral student at the Institute of Virology at Freie Universität Berlin.
The principle of live attenuated vaccines is old and is already used in measles and rubella vaccinations, for example. But in the past, scientists generated the attenuation by chance – sometimes waiting years for mutations to evolve that produced an attenuated virus. The Berlin researchers, on the other hand, were able to specifically alter the genetic code of the coronaviruses. “We wanted to prevent the attenuated viruses from mutating back into a more aggressive variant,” explains Dr. Dusan Kunec, a scientist at the Institute of Virology at Freie Universität Berlin and another co-last author of the study. “This makes our live vaccine entirely safe and means it can be tailored to new virus variants,” stresses Kunec, who was instrumental in developing the vaccine.
The next step is safety testing: The researchers are collaborating with RocketVax AG, a Swiss start-up based in Basel. The biotech company is developing the live attenuated SARS-CoV-2 vaccine and preparing a phase 1 clinical trial in humans. “We are thrilled to be at the forefront of developing and manufacturing the live attenuated SARS-CoV-2 vaccine as a nasal spray at RocketVax. Our goal is to rapidly scale-up production and advance clinical development towards market access to provide protection against post-COVID symptoms for all. We see great potential in the market for seasonal nasal vaccines”, says Dr. Vladimir Cmiljanovic, CEO of RocketVax.
The future will show which nasal vaccine will ultimately provide better protection. The manufacturers of the nasal adenovirus vaccines developed in India and China have not yet applied for approval in Europe. But one thing is clear to the scientists: since they are administered as nasal sprays or drops, nasal vaccines are a good option for use in places with limited access to trained medical staff. They are also inexpensive to produce and easy to store and transport. Last but not least, live attenuated vaccines such as this one have been proven to provide cross-protection against related viral strains, and thus presumably also against future SARS-CoV-2 variants.
Other news from the department science
Start-up Colossal Biosciences Joins Biorescue In Its Mission To Save The Northern White Rhino From Extinction
Colossal will assist the rescue mission by leveraging genome sequencing and gene editing methods to save the endangered species
"For the first time, we have systematically measured the size and abundance of cells across all major tissues and organs"
What's that smell? New gut microbe produces smelly toxic gas but protects against pathogens
Taurine-degrading bacteria influence intestinal microbiome
Wastewater treatment plants as drivers for the energy transition
Technical add-on module can, in principle, turn any wastewater treatment plant into a CO2 sink and decentralized methane production plant
At which age we are at our happiest
An evaluation of over 400 samples shows how subjective well-being develops over the course of a lifespan
New approach to testing for long Covid
Blood vessels in the eye altered with persistent coronavirus symptoms
Researchers create pioneering approaches for the detection of viral antigens
Sybodies: a revolution in biological recognition
New SARS-CoV-2 variant Eris on the rise
SARS-CoV-2 lineage EG.5.1 has an advantage at evading neutralizing antibodies
Does the human brain have an Achilles heel that ultimately leads to Autism?
CHOOSEn fate: one brain organoid’s tale on Autism
Co-crystal improves the water-solubility of ASA
This could benefit patients diagnosed with suspected acute myocardial infarction
Observing nanoparticles with unprecedented precision
Illuminated: Researchers investigate new physical phenomena on the nanoscale with microstructured fibers
Falling Walls announces Science Breakthrough of the Year 2023 laureates
“These outstanding breakthroughs will change the face of the world and impressively prove what ingenuity, curiosity and courage can achieve”
Most read news
Cells with an ear for music release insulin
For the first time, researchers are using music, including Queen's global hit "We will rock you," to stimulate insulin release from cells
"Anti-obesity drugs" normalises brain in obesity
Anti-obesity drug improves associative learning in people with obesity
Microbe of the Year 2023: Bacillus subtilis – for health and technology
Already, Bacillus subtilis is indispensable in many industries, and many more innovations are expected
Younger generation gets sick earlier and more often than older generation
In spite of their advanced age, they are in the middle of life, healthy, active and mentally alert – they are referred to as the “young old”
How sleep deprivation can harm the brain
Sleep deprivation decreases the amount of a factor that protects neurons
A whole new order of bacteria could hold the key to improving biogas production
The discovery was made by researchers from Germany, Spain and the Netherlands
How to inactivate common cold viruses
In the cold season, cold viruses are everywhere. But we can do something about it
How minimal genetic differences can turn healthy food into a deadly danger
You are what you eat - this old saying could take on a new dimension according to latest research results
New approach to testing for long Covid
Blood vessels in the eye altered with persistent coronavirus symptoms
More news from our other portals
Major breakthrough in the development of electric vehicle batteries
New study finds ways to suppress lithium plating in automotive batteries for faster charging electric vehicles
Blender Bites launches at Walmart USA
The products are to be introduced in about 1,600 stores across the country
Benchtop NMR spectroscopy can accurately analyse pyrolysis oils
More accessible analysis could help develop the potential of bio-oils as an alternative to fossil fuels
Green methanol for shipping and industry: € 10.4 Mio. for the "Leuna100" project
A consortium of two Fraunhofer institutes, DBI-Gastechnologisches Institut Freiberg, Technical University of Berlin and C1 makes industrial history at the Leuna site
Clean water from fog
A property known as photocatalytic memory ensures that this also functions when skies are overcast and at night
Green, sweet and crisp - New apple variety Pia41 approved
The apple bred at the Julius Kühn Institute receives variety protection
Research shows table salt could be the secret ingredient for better chemical recycling
Table salt as the key to the plastics recycling revolution?
Sugar: Small increase in production despite record prices
EU sugar market more than in need of reform to keep medium-sized processing companies competitive
Graphene discovery could help generate hydrogen cheaply and sustainably
Microscopic insights into electrochemical interfaces
Stanford study shows how the meat and dairy sector resists competition from alternative animal products
Scientists use quantum device to slow down simulated chemical reaction 100 billion times
What happens in femtoseconds in nature can now be observed in milliseconds in the lab
New battery holds promise for green energy
Redox-flow battery eliminates costly and inefficient membrane
Fondant under the magnifying glass
New insights into the properties of sweet coating: The results could be used to optimize the industrial production process in the future
Leipzig-based start-up converts CO₂ into green chemicals with patented plasma catalysis
CO₂ recycling as a useful complement to carbon capture and storage
A microchip for Parmigiano Reggiano cheese
Consorzio del Parmigiano Reggiano, p-Chip Corporation, and Kaasmerk Matec Partner to Launch Breakthrough in Food-Safe Digital Tracking Technology
Cleaning water with ‘smart rust’ and magnets
New method for pollutants such as crude oil, glyphosate, microplastics and hormones
A Second Life for Electric Car Batteries
Scientists develop a decision model for retired lithium-ion batteries